ATE503746T1 - Neue imidazolidinderivate - Google Patents

Neue imidazolidinderivate

Info

Publication number
ATE503746T1
ATE503746T1 AT05768418T AT05768418T ATE503746T1 AT E503746 T1 ATE503746 T1 AT E503746T1 AT 05768418 T AT05768418 T AT 05768418T AT 05768418 T AT05768418 T AT 05768418T AT E503746 T1 ATE503746 T1 AT E503746T1
Authority
AT
Austria
Prior art keywords
imidazolidine derivatives
new
new imidazolidine
alkyl group
independently selected
Prior art date
Application number
AT05768418T
Other languages
English (en)
Inventor
Kazutaka Tachibana
Haruhiko Sato
Masateru Ohta
Mitsuaki Nakamura
Takuya Shiraishi
Ikuhiro Imaoka
Hitoshi Yoshino
Masahiro Nagamuta
Hiromitsu Kawata
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE503746T1 publication Critical patent/ATE503746T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
AT05768418T 2004-08-03 2005-08-03 Neue imidazolidinderivate ATE503746T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004227321 2004-08-03
PCT/JP2005/014195 WO2006013887A1 (ja) 2004-08-03 2005-08-03 新規イミダゾリジン誘導体

Publications (1)

Publication Number Publication Date
ATE503746T1 true ATE503746T1 (de) 2011-04-15

Family

ID=35787168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05768418T ATE503746T1 (de) 2004-08-03 2005-08-03 Neue imidazolidinderivate

Country Status (7)

Country Link
US (1) US7803826B2 (de)
EP (1) EP1775289B1 (de)
JP (1) JP4912148B2 (de)
AT (1) ATE503746T1 (de)
DE (1) DE602005027213D1 (de)
TW (1) TW200612920A (de)
WO (1) WO2006013887A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031881D1 (de) * 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
US7585877B2 (en) 2005-01-10 2009-09-08 Acadia Pharmaceuticals, Inc. Aminophenyl derivatives as selective androgen receptor modulators
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1991549B1 (de) * 2006-02-10 2012-01-11 Janssen Pharmaceutica N.V. Bizyklische imidazol- oder thiadiazol-heterozyklen als selektive androgen-rezeptor-modulatoren
EP2656842B1 (de) 2006-03-27 2016-08-10 The Regents of The University of California Androgenrezeptor-modulator zur behandlung von prostatakrebs und androgenrezeptor-assoziierte erkrankungen
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
RU2319491C1 (ru) * 2006-07-12 2008-03-20 Бадулин Николай Александрович Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (ее варианты)
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
JP5659232B2 (ja) * 2009-09-10 2015-01-28 トン、ヨウヂ アンドロゲン受容体アンタゴニストおよびその使用
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
HUE037389T2 (hu) 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
WO2012119559A1 (en) 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CA3105575A1 (en) 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
EP3319939B1 (de) * 2015-07-08 2024-11-27 CV6 Therapeutics (NI) Limited Hydantoinhaltige desoxyuridin-triphosphatase-inhibitoren
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
JP4664814B2 (ja) 2003-06-12 2011-04-06 中外製薬株式会社 イミダゾリジン誘導体

Also Published As

Publication number Publication date
US20070249697A1 (en) 2007-10-25
EP1775289B1 (de) 2011-03-30
JPWO2006013887A1 (ja) 2008-05-01
DE602005027213D1 (de) 2011-05-12
EP1775289A1 (de) 2007-04-18
TW200612920A (en) 2006-05-01
EP1775289A4 (de) 2009-09-02
JP4912148B2 (ja) 2012-04-11
WO2006013887A1 (ja) 2006-02-09
US7803826B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
ATE503746T1 (de) Neue imidazolidinderivate
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
ATE338461T1 (de) Pyrazolpyrimidinfungizide
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
WO2008108380A3 (en) Pyrrole compounds
AR057914A1 (es) Compuestos organicos de azufre y su uso
EP1634874A4 (de) Imidazolidinderivate
TW200720249A (en) Pyrrolidine compound
DE602004031410D1 (de) Inden derivate als pharmazeutika
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
ATE504592T1 (de) Trehaloseverbindung und arzneimittel mit der verbindung
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200744589A (en) Pharmaceutical composition
DE602004014727D1 (de) Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung
EP2045258A4 (de) 3ý-ETHYNYLCYTIDINDERIVAT
DE60239491D1 (de) Thiazolidindionderivate und diese enthaltende pharmazeutische zusammensetzung
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
DE602004009306D1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
NO20053997D0 (no) Oligosaccharidderivat
ATE448198T1 (de) Neue alpha-ketoamidderivate und deren verwendung
MY142362A (en) Pharmaceutical composition for promoting angiogenesis
FR2870237B1 (fr) Derives arylpyrroliques, arylfulraniques et arylthiopheniques a action antitubuline, procede de preparation et utilisation en tant qu'antimitotique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties